Search results for "target"

showing 10 items of 1196 documents

Advances in the treatment of cutaneous lupus erythematosus.

2016

Lupus erythematosus (LE) is a multifactorial autoimmune disease with clinical manifestations of differing severity which may present with skin manifestations as primary sign of the disease (cutaneous lupus erythematosus, CLE) or as part of a disease spectrum (systemic lupus erythematosus, SLE). To date, no drugs are approved specifically for the treatment of CLE and only single agents have been applied in randomized controlled trials. Therefore, topical and systemic agents are used “off-label”, primarily based on open-label studies, case series, retrospective analyses, and expert opinions. In contrast, several agents, such as hydroxychloroquine, chloroquine, cyclophosphamide, azathioprine,…

0301 basic medicineCyclophosphamideDiscoid lupus erythematosusAzathioprineAntibodiesEtanerceptPolyethylene Glycols03 medical and health sciencesLupus Erythematosus DiscoidRheumatologyimmune system diseasesChloroquineMedicineHumansLupus Erythematosus SystemicMolecular Targeted TherapyPrecision Medicineskin and connective tissue diseasesRandomized Controlled Trials as TopicB-LymphocytesLupus erythematosusbusiness.industryInterleukin-6Anti-Inflammatory Agents Non-SteroidalHydroxychloroquinemedicine.diseaseBelimumab030104 developmental biologyImmunologyInterferonsbusinessBiomarkersAnti-SSA/Ro autoantibodiesmedicine.drugSignal TransductionLupus
researchProduct

The MRN complex is transcriptionally regulated by MYCN during neural cell proliferation to control replication stress

2015

The MRE11/RAD50/NBS1 (MRN) complex is a major sensor of DNA double strand breaks, whose role in controlling faithful DNA replication and preventing replication stress is also emerging. Inactivation of the MRN complex invariably leads to developmental and/or degenerative neuronal defects, the pathogenesis of which still remains poorly understood. In particular, NBS1 gene mutations are associated with microcephaly and strongly impaired cerebellar development, both in humans and in the mouse model. These phenotypes strikingly overlap those induced by inactivation of MYCN, an essential promoter of the expansion of neuronal stem and progenitor cells, suggesting that MYCN and the MRN complex migh…

0301 basic medicineDNA ReplicationTranscription GeneticDNA damageDNA repairDNA-Binding ProteinCell Cycle ProteinsBiology03 medical and health sciencesMRE11 Homologue ProteinCell Cycle ProteinStrand-Break Repair; N-Myc; Dna-Replication; Human Neuroblastoma; Feingold-Syndrome; C-Myc; Mre11-Rad50-Nbs1 Complex; Targeted Disruption; Genomic Instability; Embryonic LethalityHumansProgenitor cellMolecular BiologyneoplasmsCells CulturedNuclear ProteinCell ProliferationGeneticsNeuronsOncogene ProteinsOriginal PaperMRE11 Homologue ProteinN-Myc Proto-Oncogene ProteinCell growthDNA Repair EnzymeDNA replicationOncogene ProteinNuclear ProteinsCell BiologyNeuronCell biologyAcid Anhydride HydrolasesDNA-Binding Proteins030104 developmental biologyDNA Repair EnzymesMRN complexGene Expression RegulationRad50HumanCell Death and Differentiation
researchProduct

Kinase Inhibitors in Multitargeted Cancer Therapy

2017

The old-fashioned anticancer approaches, aiming in arresting cancer cell proliferation interfering with non-specific targets (e.g. DNA), have been replaced, in the last decades, by more specific target oriented ones. Nonetheless, single-target approaches have not always led to optimal outcomes because, for its complexity, cancer needs to be tackled at various levels by modulation of several targets. Although at present, combinations of individual single-target drugs represent the most clinically practiced therapeutic approaches, the modulation of multiple proteins by a single drug, in accordance with the polypharmacological strategy, has become more and more appealing. In the perspective of…

0301 basic medicineDrugNiacinamideIndolesPyridinesmedia_common.quotation_subjectPharmacologyBioinformaticsBiochemistryReceptor tyrosine kinase03 medical and health sciencesCrizotinibPiperidinesMultitargeted drugs anticancer agents polypharmacology tyrosine kinase receptors oncogene addiction tumor microenvironment FDA-approved drugsNeoplasmsDrug DiscoverymedicineSunitinibHumansAnilidesPyrrolesProtein Kinase Inhibitorsmedia_commonPharmacologyTumor microenvironmentbiologybusiness.industryPhenylurea CompoundsOrganic ChemistryImidazolesCancerReceptor Protein-Tyrosine KinasesSorafenibmedicine.diseaseOncogene AddictionSettore CHIM/08 - Chimica FarmaceuticaClinical trialPyridazines030104 developmental biologyMechanism of actionbiology.proteinImatinib MesylateQuinazolinesMolecular MedicinePyrazolesmedicine.symptombusinessTyrosine kinase
researchProduct

Drugs Polypharmacology by in Silico Methods: New Opportunities in Drug Discovery

2016

Background Polypharmacology, defined as the modulation of multiple proteins rather than a single target to achieve a desired therapeutic effect, has been gaining increasing attention since 1990s, when industries had to withdraw several drugs due to their adverse effects, leading to permanent injuries or death, with multi-billiondollar legal damages. Therefore, if up to then the "one drug one target" paradigm had seen many researchers interest focused on the identification of selective drugs, with the strong expectation to avoid adverse drug reactions (ADRs), very recently new research strategies resulted more appealing even as attempts to overcome the decline in productivity of the drug dis…

0301 basic medicineDrugPolypharmacologymedia_common.quotation_subjectIn silicoNanotechnology03 medical and health sciencesBiological and chemical databases computational methods Drugs multitarget activity polypharmacology repurposingDrug DiscoveryMedicineHumansComputer SimulationPolypharmacologyRepurposingmedia_commonPharmacologyMolecular Structurebusiness.industryDrug discoveryDrug repositioningIdentification (information)030104 developmental biologyRisk analysis (engineering)businessChemical databaseSoftware
researchProduct

Overview of key molecular and pharmacological targets for diabetes and associated diseases

2021

Diabetes epidemiological quantities are demonstrating one of the most important communities' health worries. The essential diabetic difficulties are including cardiomyopathy, nephropathy, inflammation, and retinopathy. Despite developments in glucose decreasing treatments and drugs, these diabetic complications are still ineffectively reversed or prohibited. Several signaling and molecular pathways are vital targets in the new therapies of diabetes. This review assesses the newest researches about the key molecules and signaling pathways as targets of molecular pharmacology in diabetes and diseases related to it for better treatment based on molecular sciences. The disease is not cured by c…

0301 basic medicineDrugmedia_common.quotation_subjectDiseaseType 2 diabetesBioinformatics030226 pharmacology & pharmacyGeneral Biochemistry Genetics and Molecular BiologyNephropathyDiabetes Complications03 medical and health sciences0302 clinical medicineDiabetes mellitusDrug DiscoveryDiabetes MellitusAnimalsHumansHypoglycemic AgentsMedicineMolecular Targeted TherapyPharmacology & PharmacyGeneral Pharmacology Toxicology and Pharmaceuticsmedia_commonGlycemicbusiness.industry0601 Biochemistry and Cell Biology 1115 Pharmacology and Pharmaceutical SciencesGeneral MedicineMolecular PharmacologyA300medicine.diseaseHuman genetics030104 developmental biologybusinessSignal Transduction
researchProduct

Dual inhibitors of histone deacetylases and other cancer-related targets: A pharmacological perspective.

2020

International audience; Epigenetic enzymes histone deacetylases (HDACs) are clinically validated anticancer drug targets which have been studied intensively in the past few decades. Although several drugs have been approved in this field, they are still limited to a subset of hematological malignancies (in particular T-cell lymphomas), with therapeutic potential not fully realized and the drug-resistance occurred after a certain period of use. To maximize the therapeutic potential of these classes of anticancer drugs, and to extend their application to solid tumors, numerous combination therapies containing an HDACi and an anticancer agent from other mechanisms are currently ongoing in clin…

0301 basic medicineDual targeting[SDV]Life Sciences [q-bio]Cancer therapyKinasesAntineoplastic AgentsBioinformaticsBiochemistryAnticancer drugsSynergistic effectsHistone Deacetylases03 medical and health sciences0302 clinical medicineDrug Delivery SystemsNeoplasmsReceptorsmedicineAnimalsHumansEpigeneticsPharmacologybiologybusiness.industryCancerDUAL (cognitive architecture)medicine.diseaseAnticancer drug3. Good healthEnzymesClinical trial[SDV] Life Sciences [q-bio]Histone Deacetylase Inhibitors030104 developmental biologyHistone030220 oncology & carcinogenesisbiology.proteinHistone deacetylases (HDACs)EpigeneticsDual inhibitorbusinessBiochemical pharmacology
researchProduct

EGFL7 - a potential therapeutic target for multiple sclerosis?

2018

0301 basic medicineEGF Family of ProteinsMultiple SclerosisClinical BiochemistryEndothelial Growth FactorsBlood–brain barrier03 medical and health sciences0302 clinical medicineDrug DiscoveryMedicineAnimalsHumansMolecular Targeted TherapyPharmacologybusiness.industryMultiple sclerosisNatalizumabCalcium-Binding Proteinsmedicine.disease030104 developmental biologymedicine.anatomical_structureBlood-Brain BarrierMolecular MedicineEGFL7businessNeuroscience030217 neurology & neurosurgeryExpert opinion on therapeutic targets
researchProduct

Nano-engineered skin mesenchymal stem cells: potential vehicles for tumour-targeted quantum-dot delivery

2017

Nanotechnology-based drug design offers new possibilities for the use of nanoparticles in imaging and targeted therapy of tumours. Due to their tumour-homing ability, nano-engineered mesenchymal stem cells (MSCs) could be utilized as vectors to deliver diagnostic and therapeutic nanoparticles into a tumour. In the present study, uptake and functional effects of carboxyl-coated quantum dots QD655 were studied in human skin MSCs. The effect of QD on MSCs was examined using a cell viability assay, Ki67 expression analysis, and tri-lineage differentiation assay. The optimal conditions for QD uptake in MSCs were determined using flow cytometry. The QD uptake route in MSCs was examined via fluore…

0301 basic medicineEndosomeGeneral Physics and Astronomyquantum dots02 engineering and technologylcsh:Chemical technologyEndocytosislcsh:TechnologyFull Research PaperFlow cytometry03 medical and health sciencesmedicineNanotechnologyendocytosislcsh:TP1-1185General Materials ScienceCD90stem cell differentiationViability assayMicropinocytosisElectrical and Electronic Engineeringlcsh:Sciencemesenchymal stem cellsmedicine.diagnostic_testlcsh:TChemistryMesenchymal stem cell021001 nanoscience & nanotechnologylcsh:QC1-999Cell biologyNanoscience030104 developmental biologyTargeted drug deliverylcsh:Q0210 nano-technologylcsh:PhysicsBeilstein Journal of Nanotechnology
researchProduct

Transient Multivalent Nanobody Targeting to CD206-Expressing Cells via PH-Degradable Nanogels

2020

To target nanomedicines to specific cells, especially of the immune system, nanobodies can be considered as an attractive tool, as they lack the Fc part as compared to traditional antibodies and, thus, prevent unfavorable Fc-receptor mediated mistargeting. For that purpose, we have site-specifically conjugated CD206/MMR-targeting nanobodies to three types of dye-labeled nanogel derivatives: non-degradable nanogels, acid-degradable nanogels (with ketal crosslinks), and single polymer chains (also obtained after nanogel degradation). All of them can be obtained from the same reactive ester precursor block copolymer. After incubation with na&iuml

0301 basic medicineEndosomeNanogels02 engineering and technologyConjugated systemArticleM2 macrophage03 medical and health sciencesHumansReversible addition−fragmentation chain-transfer polymerizationlcsh:QH301-705.5targetingchemistry.chemical_classificationRAFT polymerizationChinese hamster ovary cellGeneral MedicinePolymerHydrogen-Ion Concentrationmultivalency021001 nanoscience & nanotechnologynanobody030104 developmental biologyTAMchemistryCD206lcsh:Biology (General)nanogelclick chemistryClick chemistryBiophysicsNanocarriers0210 nano-technologyNanogelCells
researchProduct

Therapeutic targets for enterovirus infections

2020

Enteroviruses are among the most common viruses causing a huge number of acute and chronic infections leading to high economic costs. Novel nontoxic antivirals that reduce the virus load in acutely infected individuals and from various surfaces are needed to efficiently combat these viruses.This review summarizes the recent findings of compounds and tools targeting the enteroviruses and host cell molecules that are crucial for virus infection. In addition, the review states the modern methods to find new targets and tools that help to understand the mechanisms of action.High-throughput molecular screens have revealed important aspects of virus life cycle in host cells and, concomitantly, so…

0301 basic medicineEnterovirus InfectionsvirusesClinical Biochemistrymedicine.disease_causeAntiviral Agents03 medical and health sciencesCapsid0302 clinical medicineDrug DevelopmentDrug Resistance ViralDrug DiscoveryEnterovirus InfectionsAnimalsHumansMedicineMolecular Targeted TherapyVirus loadPharmacologybusiness.industryViral LoadVirologyHigh-Throughput Screening Assays030104 developmental biology030220 oncology & carcinogenesisMolecular MedicineEnterovirusbusinessExpert Opinion on Therapeutic Targets
researchProduct